In:
Blood, American Society of Hematology, Vol. 124, No. 10 ( 2014-09-04), p. 1677-1688
Abstract:
Bortezomib ameliorates sclerodermatous cGVHD responses by inhibiting germinal center B cells while maintaining GVT effects in murine models. Bortezomib provides therapeutic benefits for patients with active steroid-refractory cGVHD.
Type of Medium:
Online Resource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2014-02-554279
Language:
English
Publisher:
American Society of Hematology
Publication Date:
2014
detail.hit.zdb_id:
1468538-3
detail.hit.zdb_id:
80069-7